| scholarly article | Q13442814 |
| P50 | author | George A. Calin | Q64785850 |
| P2093 | author name string | Xiao Fu | |
| Baoqing Chen | |||
| Mihnea Dragomir | |||
| P2860 | cites work | Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 |
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma | Q24618690 | ||
| MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes | Q24644382 | ||
| The impact of microRNAs on protein output | Q24653549 | ||
| Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| CEACAM1 regulates TIM-3-mediated tolerance and exhaustion | Q28115443 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene | Q28216381 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. | Q33591618 | ||
| Reprogramming of miRNA networks in cancer and leukemia | Q33812540 | ||
| Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma | Q33889053 | ||
| Role of Stat3 in regulating p53 expression and function | Q33925115 | ||
| MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. | Q34128897 | ||
| Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression | Q34417878 | ||
| Exosomes as divine messengers: are they the Hermes of modern molecular oncology? | Q34675263 | ||
| Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c | Q35104159 | ||
| The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer | Q35399165 | ||
| B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality | Q35634896 | ||
| Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment | Q35668604 | ||
| Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies | Q35777091 | ||
| MicroRNAs and other non-coding RNAs as targets for anticancer drug development | Q35994443 | ||
| Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST | Q36015295 | ||
| The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 | ||
| MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints | Q36785139 | ||
| miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint | Q36875531 | ||
| PDL1 Regulation by p53 via miR-34 | Q36887608 | ||
| The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. | Q37564425 | ||
| PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p | Q37716640 | ||
| MicroRNA profiling in cancer | Q37869934 | ||
| Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 | ||
| Endocrine side effects induced by immune checkpoint inhibitors. | Q38087579 | ||
| MicroRNAs and ceRNAs: therapeutic implications of RNA networks | Q38221219 | ||
| MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. | Q38652482 | ||
| Monitoring immune-checkpoint blockade: response evaluation and biomarker development | Q38666241 | ||
| Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study | Q38705966 | ||
| Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma | Q38718563 | ||
| Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. | Q38883332 | ||
| Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia | Q38929504 | ||
| MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer | Q39030067 | ||
| Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics | Q39108144 | ||
| Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells | Q39298811 | ||
| New Dancing Couple: PD-L1 and MicroRNA. | Q39413337 | ||
| Circulating miRNAs in sepsis-A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis. | Q40078180 | ||
| Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. | Q41298174 | ||
| The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. | Q41348806 | ||
| miRNA-342 Regulates CEACAM1-induced Lumen Formation in a Three-dimensional Model of Mammary Gland Morphogenesis | Q41817629 | ||
| Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. | Q41899044 | ||
| miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion | Q41992370 | ||
| Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma | Q42371619 | ||
| Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. | Q47301132 | ||
| MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. | Q47726182 | ||
| Clinicopathologic implications of CD8(+)/Foxp3(+) ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. | Q47756173 | ||
| Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. | Q47799445 | ||
| MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells | Q49222124 | ||
| Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial | Q49322866 | ||
| miR-155 contributes to Df1-induced asthma by increasing the proliferative response of Th cells via CTLA-4 downregulation. | Q51175173 | ||
| B and T Lymphocyte Attenuator is a Target of miR-155 during Naïve CD4+ T Cell Activation. | Q51677446 | ||
| Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. | Q51705595 | ||
| A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding | Q83100573 | ||
| PD-1 deletion restores susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice | Q87477568 | ||
| P433 | issue | 2 | |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 103-115 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Cancer Biology & Medicine | Q26841841 |
| P1476 | title | Key questions about the checkpoint blockade-are microRNAs an answer? | |
| P478 | volume | 15 |
| Q92440937 | Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer |
| Q104495333 | Identification and validation of a miRNA-based prognostic signature for cervical cancer through an integrated bioinformatics approach |
| Q92134710 | Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer |
| Q90713822 | Role of miRNAs in immune responses and immunotherapy in cancer |
| Q89511639 | The miRNAs Role in Melanoma and in Its Resistance to Therapy |
| Q89292028 | Using microRNA Networks to Understand Cancer |
| Q58080415 | miR-155 expression in anti-tumor immunity: the higher the better? |
| Q89697863 | miRNAs as Key Players in the Management of Cutaneous Melanoma |
Search more.